In mice bearing transplantable tumors, CD137 agonist monoclonal antibodies frequently induce tumor rejection and augment tumor-specific CTL responses15,16 that are likely dependent on further crosslinking provided by Fcγ receptors. This evidence concerns the gene TNFRSF9 and neoplasm.